Please check your internet connection and try again.
# Walethmade bromide
## Overview
Walethmade bromide is a medication that has been historically used for its sedative and hypnotic properties. Its use is now largely limited due to safety concerns and the availability of safer alternatives.
## Primary Indications
Historically, Walethmade bromide was used for the short-term treatment of insomnia.
## Adult Dosing
Dosing for Walethmade bromide was highly variable and not well-standardized. Typical doses ranged from 30 mg to 120 mg orally at bedtime. Maximum recommended doses were not clearly established due to safety concerns.
## Pediatric Dosing
There is no established pediatric dosing for Walethmade bromide. Its use in children is not recommended.
## Dose Adjustments
Dose adjustments for renal or hepatic impairment were not clearly defined, but caution was advised due to potential accumulation. Elderly patients often required lower doses due to increased sensitivity.
## Contraindications
Walethmade bromide is contraindicated in patients with known hypersensitivity, severe respiratory insufficiency, sleep apnea, or myasthenia gravis.
## Adverse Effects
Common adverse effects include drowsiness, dizziness, confusion, ataxia, headache, and gastrointestinal upset. More serious adverse effects can include paradoxical excitation, respiratory depression, and dependence.
## Key Drug Interactions
Concomitant use with other CNS depressants (e.g., alcohol, opioids, benzodiazepines, antihistamines) can potentiate sedation and respiratory depression.
## Monitoring
Patients should be monitored for excessive sedation, respiratory status, and signs of dependence or withdrawal.
## Clinical Pearls
Due to its significant safety risks, including respiratory depression and potential for dependence, Walethmade bromide is rarely used in modern practice. Safer alternatives for insomnia are generally preferred.
**Please verify current prescribing information with the latest product monograph or reliable drug compendium as drug information is subject to change and local protocols may apply.**
